Table II-IAdverse Events

Toxicity TypeStudySeverity or GradeResults
HER2 Discrepant (IHC 2+/FISH+)
Treatment-related mortalityF/U (mo)Grp1 n%Grp2 n%
NauseaF/U (mo)Grp1 n%Grp2 n%
VomitingF/U (mo)Grp1 n%Grp2 n%
AnorexiaF/U (mo)Grp1 n%Grp2 n%
LethargyF/U (mo)Grp1 n%Grp2 n%
NeurosensoryF/U (mo)Grp1 n%Grp2 n%
Hearing lossF/U (mo)Grp1 n%Grp2 n%
Cardiac ischemiaF/U (mo)Grp1 n%Grp2 n%
Diminished LVEFF/U (mo)Grp1 n%Grp2 n%
ArrhythmiasF/U (mo)Grp1 n%Grp2 n%
BronchopulmonaryF/U (mo)Grp1 n%Grp2 n%
DermatologicF/U (mo)Grp1 n%Grp2 n%
KidneyF/U (mo)Grp1 n%Grp2 n%
AnemiaF/U (mo)Grp1 n%Grp2 n%
ThrombocytopeniaF/U (mo)Grp1 n%Grp2 n%
Leukopenia or neutropeniaF/U (mo)Grp1 n%Grp2 n%
InfectionF/U (mo)Grp1 n%Grp2 n%
OtherF/U (mo)Grp1 n%Grp2 n%
HER2 Negative
Treatment-related mortalityF/U (mo)Grp1 n%Grp2 n%
NauseaF/U (mo)Grp1 n%Grp2 n%
VomitingF/U (mo)Grp1 n%Grp2 n%
AnorexiaF/U (mo)Grp1 n%Grp2 n%
LethargyF/U (mo)Grp1 n%Grp2 n%
NeurosensoryF/U (mo)Grp1 n%Grp2 n%
Hearing lossF/U (mo)Grp1 n%Grp2 n%
Cardiac ischemiaF/U (mo)Grp1 n%Grp2 n%
Diminished LVEFF/U (mo)Grp1 n%Grp2 n%
ArrhythmiasF/U (mo)Grp1 n%Grp2 n%
BronchopulmonaryF/U (mo)Grp1 n%Grp2 n%
DermatologicF/U (mo)Grp1 n%Grp2 n%
KidneyF/U (mo)Grp1 n%Grp2 n%
AnemiaF/U (mo)Grp1 n%Grp2 n%
ThrombocytopeniaF/U (mo)Grp1 n%Grp2 n%
Leukopenia or neutropeniaF/U (mo)Grp1 n%Grp2 n%
InfectionF/U (mo)Grp1 n%Grp2 n%
OtherF/U (mo)Grp1 n%Grp2 n%

From: Appendix C. Evidence Data Abstraction Tables

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.